ArticleNature medicine2018
De novo NAD
Registry-linked trialAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06521307 (Impact of Nicotinamide Riboside), which is not on this map. Cited by 229 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
229citing papers in PubMed, 2 pooled it
13.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery.A Randomized Controlled Pilot Study
Who cites it
229 citing papers in PubMed, 2 syntheses or guidelines pooled it, 355 citations in OpenAlex.
- Preclinical models versus clinical renal ischemia reperfusion injury: A systematic review based on metabolic signatures.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Pooled it
- States of quinolinic acid excess in urine: A systematic review of human studies.Frontiers in nutrition · 2022Pooled it
- The differential impact of three different NADNature metabolism · 2026Trial
- Nicotinamide riboside with pterostilbene (NRPT) increases NADBMC nephrology · 2020Trial
- Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol.Kidney international reports · 2026Article
- Spatial analysis reveals cellular microenvironments and mechanisms of inflammation and injury in acute interstitial nephritis.Nature communications · 2026Article
- Preclinical evidence for supra-clinical acute kidney injury: current biomarkers are not enough.Intensive care medicine experimental · 2026Article
- Rewiring the mitochondrial NADMaterials today. Bio · 2026Article
- Purine-Metabolism Reprogramming Associated with Failed-Repair Proximal Tubule States in the AKI-to-CKD Transition.Metabolites · 2026Article
- Untargeted metabolomics reveals distinct metabolic profiles in MUT-type methylmalonic acidemia.Molecular and cellular pediatrics · 2026Article
- The Aging Kidney and Acute Kidney Injury.Journal of the American Society of Nephrology : JASN · 2026Review
- Effects of NAD⁺ repletion with Nicotinamide riboside on obesity-induced chronic kidney disease and renal cell lipotoxicity.Scientific reports · 2026Article
- Integrating metabolomics and machine learning with in silico analysis to identify early biomarkers and molecular interactions in sepsis-associated acute kidney injury.Scientific reports · 2026Article
- Urinary Metabolomics Predict Acute Kidney Injury in Very-Low-Birth-Weight Infants with Patent Ductus Arteriosus.Biomolecules · 2026Article
- Article
- The global epidemiology of acute kidney injury: challenges and opportunities.Nature reviews. Nephrology · 2026Review
- NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations.JCI insight · 2026Article
- Precision Nanodelivery Enables Spatiotemporal Control of NAD⁺ Metabolism in Ageing and Disease.International journal of nanomedicine · 2026Review
- Indoleamine 2,3-dioxygenase-regulated macrophages metabolic reprogramming rescues tacrolimus-induced nephrotoxicity.Frontiers in pharmacology · 2026Article
- Pharmacological profiling of intravenous MP-04: sustained NADFrontiers in pharmacology · 2026Article
169 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byModulating NAD2018
- Commented on byAugmenting NAD2018
- Commented on by
Authors and funding
21 authors at 4 institutions in 1 country.
Ali Poyan MehrDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5610-2979
Mei T TranDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Kenneth M RaltoDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
David E LeafDivision of Renal Medicine and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Vaughan WashcoDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Joseph MessmerDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Adam LernerDepartment of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Ajay KherDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Steven H KimDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Charbel C KhouryDivision of Nephrology and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Shoshana J HerzigDivision of General Medicine and Primary Care Medicine and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Mary E TrovatoCardiovascular Institute and Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Noemie Simon-TillauxDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Matthew R LynchDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Ravi I ThadhaniDivision of Nephrology and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Clary B ClishBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8259-9245
Kamal R KhabbazCardiovascular Institute and Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Eugene P RheeDivision of Nephrology and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Sushrut S WaikarDivision of Renal Medicine and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Anders H BergDivision of Clinical Chemistry and Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Samir M ParikhDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. sparikh1@bidmc.harvard.edu.ORCID http://orcid.org/0000-0002-1038-981X
Beth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USBroad Institute · USHarvard University · US
Funding
TRAINING IN CELL STRUCTURE AND FUNCTION IN NEPHROLOGYT32DK007540 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BROWN, DENNIS, SOBERMAN, ROY · 1986 to 2021
$7.2MTie2-driven vascular control in critical illnessR35HL139424 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI PARIKH, SAMIR M · 2018 to 2024
$6.4MRESEARCH TRAINING IN NEPHROLOGYT32DK007199 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI POLLAK, MARTIN R. · 1986 to 2022
$6.0MMitochondrial Biogenesis in Kidney DiseaseR01DK095072 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Samir M Parikh · 2012 to 2026
$5.3MTargeting the Endothelium in SepsisR01HL125275 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FLAUMENHAFT, ROBERT C, PARIKH, SAMIR M · 2014 to 2018
$4.2MDysregulated Mineral Metabolism and Acute Kidney InjuryK23DK106448 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI LEAF, DAVID EVAN · 2015 to 2019
$964kImproving Use of Sedating Medications in Hospitalized Older AdultsK23AG042459 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI HERZIG, SHOSHANA J · 2013 to 2017
$783kThe role of carbamylation in uremia associated heart diseaseK08HL121801 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BERG, ANDERS HAYDEN · 2014 to 2017
$588kProtein carbamylation and uremic cardiomyopathy in chronic kidney diseaseR56HL133399 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BERG, ANDERS HAYDEN · 2016 to 2016
$433kNHLBI NIH HHS K08 HL121801NHLBI NIH HHS R01 HL125275NHLBI NIH HHS R35 HL139424NHLBI NIH HHS R56 HL133399NIA NIH HHS K23 AG042459NIDDK NIH HHS K23 DK106448NIDDK NIH HHS R01 DK095072NIDDK NIH HHS T32 DK007199NIDDK NIH HHS T32 DK007540
Abstract
Nicotinamide adenine dinucleotide (NAD
Indexed as
Biosynthetic PathwaysAcute Kidney InjuryAgedAnimalsCardiac Surgical ProceduresHumansIschemiaMiceMiddle AgedNADNiacinamideNicotinate-Nucleotide Diphosphorylase (Carboxylating)PentosyltransferasesPilot ProjectsQuinolinic AcidTreatment OutcomeNADNiacinamideNicotinate-Nucleotide Diphosphorylase (Carboxylating)PentosyltransferasesQuinolinic AcidTryptophan
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06521307ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.